Skye Bioscience, Inc. Proceeds from Debt, Net of Issuance Costs
Skye Bioscience, Inc. (SKYE) reported Proceeds from Debt, Net of Issuance Costs of $450.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-02.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2021-03-02
- Skye Bioscience, Inc. proceeds from debt, net of issuance costs for the quarter ending 2020-12-31 was $0.00.
- Skye Bioscience, Inc. proceeds from debt, net of issuance costs for the quarter ending 2020-09-30 was $0.00.
- Skye Bioscience, Inc. proceeds from debt, net of issuance costs for the quarter ending 2019-12-31 was $0.00.
- Skye Bioscience, Inc. proceeds from debt, net of issuance costs for the quarter ending 2019-09-30 was $0.00.
- Skye Bioscience, Inc. proceeds from debt, net of issuance costs for fiscal 2020 was $450.00K, a 88.72% decline from fiscal 2019.
- Skye Bioscience, Inc. proceeds from debt, net of issuance costs for fiscal 2019 was $3.99M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $0.00 derived: sum of 2 quarters · filed 2021-03-02 | $450.00K 10-K · filed 2021-03-02 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $450.00K 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | $450.00K 10-Q · filed 2020-08-13 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $0.00 derived: sum of 2 quarters · filed 2021-03-02 | $3.99M 10-K · filed 2021-03-02 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $3.99M 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $3.99M 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |